Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for Alpelisib-Induced Hyperglycemia in Metastatic Breast Cancer
NCT05753657Phase 1Recruiting
- Sponsor
- Rambam Health Care Campus
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pioglitazone in hyperglycemia and hyperinsulinemia, sponsored by Rambam Health Care Campus. Primary endpoints: Rate of severe (grade 3 and 4) hyperglycemia at 1 year, Rate of all grade hyperglycemia at 1 year and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
pioglitazone
03
Conditions
hyperglycemiahyperinsulinemia
Beyond the preview
Go deeper on NCT05753657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753657.